ATE238733T1 - Inhalierbares kontrastmittel - Google Patents

Inhalierbares kontrastmittel

Info

Publication number
ATE238733T1
ATE238733T1 AT95905462T AT95905462T ATE238733T1 AT E238733 T1 ATE238733 T1 AT E238733T1 AT 95905462 T AT95905462 T AT 95905462T AT 95905462 T AT95905462 T AT 95905462T AT E238733 T1 ATE238733 T1 AT E238733T1
Authority
AT
Austria
Prior art keywords
patient
contrast agent
inhalable
lungs
agent
Prior art date
Application number
AT95905462T
Other languages
English (en)
Inventor
Gary H Brandenburger
Gary L Cantrell
Original Assignee
Mallinckrodt Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Inc filed Critical Mallinckrodt Inc
Application granted granted Critical
Publication of ATE238733T1 publication Critical patent/ATE238733T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
AT95905462T 1993-12-23 1994-12-22 Inhalierbares kontrastmittel ATE238733T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/172,100 US5406950A (en) 1993-12-23 1993-12-23 Inhalable contrast agent
PCT/US1994/014852 WO1995017125A1 (en) 1993-12-23 1994-12-22 Inhalable contrast agent

Publications (1)

Publication Number Publication Date
ATE238733T1 true ATE238733T1 (de) 2003-05-15

Family

ID=22626366

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95905462T ATE238733T1 (de) 1993-12-23 1994-12-22 Inhalierbares kontrastmittel

Country Status (9)

Country Link
US (1) US5406950A (de)
EP (1) EP0802767B1 (de)
JP (1) JP3881007B2 (de)
AT (1) ATE238733T1 (de)
AU (1) AU1406895A (de)
CA (1) CA2179617A1 (de)
DE (1) DE69432607T2 (de)
ES (1) ES2199237T3 (de)
WO (1) WO1995017125A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9205298A (es) * 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
DE69230885T3 (de) * 1991-09-17 2008-01-24 Ge Healthcare As Gasförmige ultraschallkontrastmittel
US6723303B1 (en) 1991-09-17 2004-04-20 Amersham Health, As Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane
US6875420B1 (en) 1991-09-17 2005-04-05 Amersham Health As Method of ultrasound imaging
US5558855A (en) * 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
CZ191695A3 (en) * 1993-01-25 1996-05-15 Sonus Pharma Inc Biologically compatible contrast agent, process of its preparation and representation method by ultrasound
IL108416A (en) 1993-01-25 1998-10-30 Sonus Pharma Inc Colloids with phase difference as contrast ultrasound agents
US5855775A (en) 1995-05-05 1999-01-05 Kerfoot; William B. Microporous diffusion apparatus
USRE43350E1 (en) 1995-05-05 2012-05-08 Think Village-Kerfoot, Llc Microporous diffusion apparatus
EP0831935A4 (de) * 1995-06-07 2001-08-29 Mallinckrodt Medical Inc Gasförmige ultraschallkontrastmittel und dazugehörige verfahren
US6167297A (en) * 1999-05-05 2000-12-26 Benaron; David A. Detecting, localizing, and targeting internal sites in vivo using optical contrast agents
US6689062B1 (en) 1999-11-23 2004-02-10 Microaccess Medical Systems, Inc. Method and apparatus for transesophageal cardiovascular procedures
US6210611B1 (en) 1999-11-30 2001-04-03 Duke University Methods for producing gas microbubbles having lipid-containing shells formed thereon
US6436285B1 (en) * 1999-12-22 2002-08-20 William B. Kerfoot Laminated microporous diffuser
US8557110B2 (en) * 2000-07-06 2013-10-15 Thinkvillage-Kerfoot, Llc Groundwater and subsurface remediation
US6582611B1 (en) 2000-07-06 2003-06-24 William B. Kerfoot Groundwater and subsurface remediation
WO2002026231A1 (en) * 2000-09-26 2002-04-04 Georgetown University Use of nitroxides for the treatment of vascular disorders in a diabetic mammal
GB0123013D0 (en) * 2001-09-25 2001-11-14 Upperton Ltd Improvements relating to imaging contrast agents
US6913251B2 (en) 2003-02-12 2005-07-05 William B. Kerfoot Deep well sparging
US7666316B2 (en) 2004-07-20 2010-02-23 Thinkvillage-Kerfoot, Llc Permanganate-coated ozone for groundwater and soil treatment with in-situ oxidation
US8302939B2 (en) * 2003-02-12 2012-11-06 Thinkvillage-Kerfoot, Llc Soil and water remediation system and method
US7442313B2 (en) * 2003-08-27 2008-10-28 Thinkvillage-Kerfoot, Llc Environmental remediation method and system
US7547388B2 (en) * 2004-07-20 2009-06-16 Think Village-Kerfoot, Llc Superoxidant poiser for groundwater and soil treatment with in-situ oxidation-reduction and acidity-basicity adjustment
US20060248944A1 (en) * 2003-04-15 2006-11-09 Koninklijke Philips Electronics N.V. Method to determine the spatial distribution of magnetic particles and magnetic particle administering compositions
US7569140B2 (en) * 2005-11-10 2009-08-04 Thinkvillage-Kerfoot, Llc Directional spargewell system
US7401767B2 (en) * 2003-12-24 2008-07-22 Kerfoot William B Directional microporous diffuser and directional sparging
US7651611B2 (en) * 2006-07-12 2010-01-26 Thinkvillage-Kerfoot, Llc Directional microporous diffuser and directional sparging
US8771507B2 (en) 2003-12-24 2014-07-08 Thinkvillage-Kerfoot, Llc Directional microporous diffuser and directional sparging
US7621696B2 (en) * 2006-07-12 2009-11-24 Thinkvillage-Kerfoot, Llc Directional microporous diffuser and directional sparging
CA2554078A1 (en) * 2004-01-23 2005-08-04 Sri International Optical vascular function imaging system and method for detection and diagnosis of cancerous tumors
US20050215954A1 (en) * 2004-03-29 2005-09-29 Mallinckrodt Inc. Apparatus and method for maintaining suspendible agents in suspension
US8012457B2 (en) * 2004-06-04 2011-09-06 Acusphere, Inc. Ultrasound contrast agent dosage formulation
CA2602385A1 (en) * 2005-03-29 2006-10-05 The Research Foundation Of State University Of New York Hybrid inorganic nanoparticles, methods of using and methods of making
WO2007087398A2 (en) * 2006-01-25 2007-08-02 The Trustees Of Columbia University In The City Of New York Systems and methods for imaging a blood vessel using temperature sensitive magnetic resonance imaging
US7820137B2 (en) * 2006-08-04 2010-10-26 Enerdel, Inc. Lithium titanate and method of forming the same
US8771170B2 (en) * 2008-08-01 2014-07-08 Microaccess, Inc. Methods and apparatus for transesophageal microaccess surgery
WO2011035140A1 (en) 2009-09-18 2011-03-24 Paka Pulmonary Pharmaceuticals, Inc. Methods and compositions for delivery of contrast moieties to the lungs
US9265483B2 (en) 2010-08-06 2016-02-23 The Trustees Of Columbia University In The City Of New York Medical imaging contrast devices, methods, and systems
US9694401B2 (en) 2013-03-04 2017-07-04 Kerfoot Technologies, Inc. Method and apparatus for treating perfluoroalkyl compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US5132409A (en) * 1987-01-12 1992-07-21 Bracco Industria Chimica S.P.A. Macrocyclic chelating agents and chelates thereof
EP0442962B1 (de) * 1988-11-09 1994-01-05 UNGER, Evan C Liposomale radiologische kontrastmittel
FR2644059B1 (fr) * 1989-03-08 1994-03-04 Fabre Medicament Pierre Compositions aerosols destinees a l'imagerie, au diagnostic et a la therapie ciblee de foyers inflammatoires et tumoraux
US5088499A (en) * 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
GB9003821D0 (en) * 1990-02-20 1990-04-18 Danbiosyst Uk Diagnostic aid
FR2659351B1 (fr) * 1990-03-08 1994-12-02 Pf Medicament Compose polysaccharidique delipide, procede de preparation, compositions en comprenant.
US5215680A (en) * 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
US5147631A (en) * 1991-04-30 1992-09-15 Du Pont Merck Pharmaceutical Company Porous inorganic ultrasound contrast agents
GB9116610D0 (en) * 1991-08-01 1991-09-18 Danbiosyst Uk Preparation of microparticles
DE69230885T3 (de) * 1991-09-17 2008-01-24 Ge Healthcare As Gasförmige ultraschallkontrastmittel
WO1993006869A1 (en) * 1991-10-04 1993-04-15 Mallinckrodt Medical, Inc. Gaseous ultrasound contrast agents
US5693337A (en) * 1994-07-13 1997-12-02 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion

Also Published As

Publication number Publication date
WO1995017125A1 (en) 1995-06-29
US5406950A (en) 1995-04-18
JP3881007B2 (ja) 2007-02-14
DE69432607D1 (de) 2003-06-05
EP0802767A4 (de) 1999-06-23
DE69432607T2 (de) 2004-03-18
JPH09507078A (ja) 1997-07-15
AU1406895A (en) 1995-07-10
EP0802767B1 (de) 2003-05-02
ES2199237T3 (es) 2004-02-16
EP0802767A1 (de) 1997-10-29
CA2179617A1 (en) 1995-06-29

Similar Documents

Publication Publication Date Title
ATE238733T1 (de) Inhalierbares kontrastmittel
MY109875A (en) Novel formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight surfactants.
AU8115898A (en) Methods of photoacoustic imaging
ES2117642T3 (es) Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
DE69420412D1 (de) Therapeutisches inhalationspräparat
EP1019072A4 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
IL76119A (en) Device for initiating reperfusion treatment when heart attack symptoms are present
ES2159630T3 (es) Sistema de administracion por via oral de proteinas g-csf quimicamente modificadas.
CA2041579A1 (en) Dosage form
EP0962225A3 (de) Verwendung von Phentolamin zur Herstellung eines Arzneimittels zur Behandlung von erektiler Funktionsstörung
MY101026A (en) An improved method for administering insulin.
IL123595A (en) Hydrolysis-promoting taxane hydrophobic derivatives and pharmaceutical compositions containing them
ZA874812B (en) Drug
GB9023701D0 (en) Medical treatment
JP2001515053A (ja) 造影剤におけるまたは造影剤に関する改良
EP0280135A3 (en) Protein c-inhibitor (pci) as a pharmaceutical and diagnostic agent, process for the preparation of such a pharmaceutical or diagnostic agent and a composition containing pci
RU2012363C1 (ru) Устройство в.а.старцева для насыщения воздуха лекарственными веществами
NIKOLAYEV et al. Demonstration of gas bubbles in canine pulmonary artery and aorta by means of ultrasonic echography with intravenous air infusion
GB2019720A (en) S-adenosyl-L-homocysteine and salts thereof for use in therapy
Aloj et al. Clinic evaluation of kedacillin in complicated biliary surgery.
JPS6463514A (en) Improvement in biologically using ability of drug
WO1998003205A3 (en) Enhanced ultrasound contrast imaging using inhaled gases
UA7190A (uk) Спосіб лікування запально-гнійних захворювань легень
GEU1998346Y (en) Method for Diagnosis of Uterine Tubes Pathology
MY117556A (en) Methods and formulations for modulating the human sexual response

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties